Phase I and pharmacokinetic (PK) study of PTK787/ZK222584 (PTK/ZK) plus capecitabine (cape) in patients (Pts) with advanced cancer

被引：0
|
作者：
Schilsky, R. L.
Geary, D.
Skoog, L.
Desai, A.
Valickas, J.
Masson, E.
Laurent, D.
Pendowski, C.
Vokes, E.
Ratain, M.
机构：
[1] Univ Chicago, Chicago, IL 60637 USA
[2] Novartis Oncol, E Hanover, NJ USA
[3] Schering AG, Berlin, Germany
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2007年 / 25卷 / 18期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
3595
引用
收藏
页数：1
相关论文
共 50 条
  • [21] A phase I trial of PTK787/ZK 222584 (PTK/ZK), a novel oral VEGF-R TK inhibitor in patients with recurrent GBM.
    Friedman, HS
    Yung, WA
    Jackson, E
    Provenzale, J
    Leeds, N
    Conrad, C
    Walker, A
    Henry, A
    Laurent, D
    Dugan, M
    CLINICAL CANCER RESEARCH, 2001, 7 (11) : 3665S - 3665S
  • [22] Phase 1-2 Trial of PTK787/ZK222584 Combined With Intravenous Doxorubicin for Treatment of Patients With Advanced Hepatocellular Carcinoma
    Yau, Thomas
    Chan, Pierre
    Pang, Roberta
    Ng, Kelvin
    Fan, S. T.
    Poon, Ronnie T.
    CANCER, 2010, 116 (21) : 5022 - 5029
  • [23] Vascular density analysis in colorectal cancer patients treated with vatalanib (PTK787/ZK222584) in the randomised CONFIRM trials
    A Giatromanolaki
    M I Koukourakis
    E Sivridis
    K C Gatter
    T Trarbach
    G Folprecht
    M M Shi
    D Lebwohl
    T Jalava
    D Laurent
    G Meinhardt
    A L Harris
    British Journal of Cancer, 2012, 107 : 1044 - 1050
  • [24] Antiangiogeness as new treatment modality in ovarian cancer: a phase lb, open label, safety and pharmacokinetics (PK) study of escalating doses of PTK787/ZK222584 (PTK/ZK) in combination with paclitaxel and carboplatin in patients (pts) with stage IC to IV epithelial ovarian cancer
    Schroeder, W.
    Abadie, S.
    Witteveen, P. O.
    Campone, M.
    Viens, P.
    Jalava, T.
    Masson, E.
    Bilic, S.
    Chlistalla, A.
    du Bois, A.
    EJC SUPPLEMENTS, 2005, 3 (02): : 273 - 273
  • [25] PTK787/ZK 222584 (PTK/ZK), an oral tyrosine kinase inhibitor, has activity in patients with agnogenic myeloid metaplasia (AMM).
    Giles, Francis J.
    Carroll, Michael
    List, Alan
    Ferrajoli, Alessandra
    Thomas, Deborah
    Cortes, Jorge
    Feldman, Eric
    Roboz, Gail
    BLOOD, 2006, 108 (11) : 317B - 317B
  • [26] Vascular density analysis in colorectal cancer patients treated with vatalanib (PTK787/ZK222584) in the randomised CONFIRM trials
    Giatromanolaki, A.
    Koukourakis, M. I.
    Sivridis, E.
    Gatter, K. C.
    Trarbach, T.
    Folprecht, G.
    Shi, M. M.
    Lebwohl, D.
    Jalava, T.
    Laurent, D.
    Meinhardt, G.
    Harris, A. L.
    BRITISH JOURNAL OF CANCER, 2012, 107 (07) : 1044 - 1050
  • [27] Phase I/II study of PTK787/ZK 222584 (PTK/ZK), a nove, oral angiogenesis inhibitor in combination with FOLFIRI as first-line treatment for patients with metastatic colorectal cancer
    Vanhoefer, U.
    Trarbach, T.
    Schleucher, N.
    Junker, U.
    Tewes, M.
    Masson, E.
    Lebwohl, D.
    Seeber, S.
    Laurent, D.
    ANNALS OF ONCOLOGY, 2004, 15 : 94 - 95
  • [28] PTK787/ZK222584, an inhibitor of VEGF receptor tyrosine kinases, decreases glioma growth and vascularization
    Goldbrunner, R
    Bendszus, M
    Wood, J
    Kiderlen, M
    Miebach, S
    Tonn, JC
    JOURNAL OF VASCULAR RESEARCH, 2004, 41 (01) : 96 - 96
  • [29] Phase I study of the oral vascular endothelial growth factor (VEGF) receptor inhibitor PTK787/ZK222584 on a twice daily schedule in patients with advanced cancer.
    Thomas, A
    Morgan, B
    Rowark, G
    Mason, C
    Henry, A
    Pfister, C
    Moss, D
    Unger, C
    Drevs, J
    O'Byrne, K
    Laurent, D
    Dugan, M
    Steward, W
    CLINICAL CANCER RESEARCH, 2001, 7 (11) : 3662S - 3663S
  • [30] Phase I study of the novel, oral angiogenesis inhibitor PTK787/ZK 222584 (PTK/ZK): Evaluating the pharmacokinetic effect of a high-fat meal in patients with hormone-refractory prostate cancer (HRPC).
    George, D
    Oh, W
    Gilligan, T
    Masson, E
    Souppart, C
    Wang, Y
    Ho, Y
    Lebwohl, D
    Laurent, D
    Kantoff, P
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 428S - 428S
12345